Ser2481-autophosphorylated mTOR colocalizes with chromosomal passenger proteins during mammalian cell cytokinesis

Cell Cycle

Volumn 11, Issue 22, 2012, Pages 4211-4221

  Vazquez Martin, Alejandro ^a,b   Sauri Nadal, Tamara ^a,b   Menendez, Octavio J ^a,b   Oliveras Ferraros, Cristina ^a,b   Cufí, Sílvia ^a,b   Corominas Faja, Bruna ^a,b   López Bonet, Eugeni ^b,c   Menendez, Javier A ^a,b  

^a CATALAN INSTITUTE OF ONCOLOGY   (Spain)

^b GIRONA BIOMEDICAL RESEARCH INSTITUTE IDIBGI   (Spain)

^c HOSPITAL JOSEP TRUETA   (Spain)

Author keywords

Chromosomal passenger protein; Mitosis; mTOR; mTORC; Rapamycin

Indexed keywords

CHROMOSOMAL PASSENGER PROTEIN; MAMMALIAN TARGET OF RAPAMYCIN; NOCODAZOLE; UNCLASSIFIED DRUG;

ARTICLE; AUTOPHOSPHORYLATION; CARCINOMA CELL; CELL DIVISION; CELLULAR DISTRIBUTION; CHROMOSOME; CYTOKINESIS; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE; MITOSIS; MOLECULAR DYNAMICS; PROTEIN FUNCTION;

EID: 84869391341     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.4161/cc.22551     Document Type: Article

References (47)

1. Bjornsti MA, Houghton PJ. The TOR pathway: a target for cancer therapy. Nat Rev Cancer 2004; 4:335-48; PMID:15122205; http://dx.doi.org/10.1038/nrc1362.
2. Wullschleger S, Loewith R, Hall MN. TOR signaling in growth and metabolism. Cell 2006; 124:471- 84; PMID:16469695; http://dx.doi.org/10.1016/j. cell.2006.01.016.
3. Sabatini DM. mTOR and cancer: insights into a complex relationship. Nat Rev Cancer 2006; 6:729-34; PMID:16915295; http://dx.doi.org/10.1038/nrc1974.
4. Guertin DA, Sabatini DM. Defining the role of mTOR in cancer. Cancer Cell 2007; 12:9-22; PMID:17613433; http://dx.doi.org/10.1016/j.ccr.2007.05.008.
5. Bhaskar PT, Hay N. The two TORCs and Akt. Dev Cell 2007; 12:487-502; PMID:17419990; http://dx.doi.org/10.1016/j.devcel.2007.03.020.
6. Hall MN. mTOR-what does it do? Transplant Proc 2008; 40(Suppl):S5-8; PMID:19100909; http://dx.doi.org/10.1016/j.transproceed.2008.10.009.
7. Peterson RT, Beal PA, Comb MJ, Schreiber SL. FKBP12-rapamycin-associated protein (FRAP) autophosphorylates at serine 2481 under translationally repressive conditions. J Biol Chem 2000; 275:7416-23; PMID:10702316; http://dx.doi.org/10.1074/jbc.275.10.7416.
8. Chiang GG, Abraham RT. Phosphorylation of mammalian target of rapamycin (mTOR) at Ser-2448 is mediated by p70S6 kinase. J Biol Chem 2005; 280:25485-90; PMID:15899889; http://dx.doi.org/10.1074/jbc.M501707200.
9. Holz MK, Blenis J. Identification of S6 kinase 1 as a novel mammalian target of rapamycin (mTOR)-phosphorylating kinase. J Biol Chem 2005; 280:26089-93; PMID:15905173; http://dx.doi.org/10.1074/jbc.M504045200.
10. Copp J, Manning G, Hunter T. TORC-specific phosphorylation of mammalian target of rapamycin (mTOR): phospho-Ser2481 is a marker for intact mTOR signaling complex 2. Cancer Res 2009; 69:1821-7; PMID:19244117; http://dx.doi.org/10.1158/0008-5472.CAN-08-3014.
11. Sarbassov DD, Ali SM, Sengupta S, Sheen JH, Hsu PP, Bagley AF, et al. Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB. Mol Cell 2006; 22:159-68; PMID:16603397; http://dx.doi.org/10.1016/j.molcel.2006.03.029.
12. Soliman GA, Acosta-Jaquez HA, Dunlop EA, Ekim B, Maj NE, Tee AR, et al. mTOR Ser-2481 autophosphorylation monitors mTORC-specific catalytic activity and clarifies rapamycin mechanism of action. J Biol Chem 2010; 285:7866-79; PMID:20022946; http://dx.doi.org/10.1074/jbc.M109.096222.
13. Yaba A, Bianchi V, Borini A, Johnson J. A putative mitotic checkpoint dependent on mTOR function controls cell proliferation and survival in ovarian granulosa cells. Reprod Sci 2008; 15:128-38; PMID:18276949; http://dx.doi.org/ 10.1177/1933719107312037.
14. Yu J, Yaba A, Kasiman C, Thomson T, Johnson J. mTOR controls ovarian follicle growth by regulating granulosa cell proliferation. PLoS One 2011; 6:e21415; PMID:21750711; http://dx.doi.org/10.1371/journal.pone.0021415.
15. Doghman M, El Wakil A, Cardinaud B, Thomas E, Wang J, Zhao W, et al. Regulation of insulin-like growth factor-mammalian target of rapamycin signaling by microRNA in childhood adrenocortical tumors. Cancer Res 2010; 70:4666-75; PMID:20484036; http://dx.doi.org/10.1158/0008-5472.CAN-09-3970.
16. Vazquez-Martin A, Oliveras-Ferraros C, Bernadó L, López-Bonet E, Menendez JA. The serine 2481-autophosphorylated form of mammalian Target Of Rapamycin (mTOR) is localized to midzone and midbody in dividing cancer cells. Biochem Biophys Res Commun 2009; 380:638-43; PMID:19285014; http://dx.doi.org/10.1016/j.bbrc.2009.01.153.
17. Lopez-Bonet E, Vazquez-Martin A, Pérez-Martínez MC, Oliveras-Ferraros C, Pérez-Bueno F, Bernadó L, et al. Serine 2481-autophosphorylation of mammalian target of rapamycin (mTOR) couples with chromosome condensation and segregation during mitosis: confocal microscopy characterization and immunohistochemical validation of PP-mTOR(Ser2481) as a novel high-contrast mitosis marker in breast cancer core biopsies. Int J Oncol 2010; 36:107-15; PMID:19956839.
18. Vazquez-Martin A, López-Bonet E, Oliveras-Ferraros C, Pérez-Martínez MC, Bernadó L, Menendez JA. Mitotic kinase dynamics of the active form of AMPK (phospho-AMPKalphaThr172) in human cancer cells. Cell Cycle 2009; 8:788-91; PMID:19221486; http://dx.doi.org/10.4161/cc.8. 5.7787.
19. Vazquez-Martin A, Oliveras-Ferraros C, Menendez JA. The active form of the metabolic sensor: AMPactivated protein kinase (AMPK) directly binds the mitotic apparatus and travels from centrosomes to the spindle midzone during mitosis and cytokinesis. Cell Cycle 2009; 8:2385-98; PMID:19556893; http://dx.doi.org/10.4161/cc.8.15.9082.
20. Vazquez-Martin A, Oliveras-Ferraros C, Lopez-Bonet E, Menendez JA. AMPK: Evidence for an energy-sensing cytokinetic tumor suppressor. Cell Cycle 2009; 8:3679-83; PMID:19844168; http://dx.doi.org/10.4161/cc.8.22.9905.
21. Vazquez-Martin A, Oliveras-Ferraros C, Cufí S, Menendez JA. Polo-like kinase 1 regulates activation of AMP-activated protein kinase (AMPK) at the mitotic apparatus. Cell Cycle 2011; 10:1295-302; PMID:21474997; http://dx.doi.org/10.4161/cc.10.8.15342.
22. Menendez JA, Vazquez-Martin A. AMPK: A bona fide resident of the mitotic spindle midzone. Cell Cycle 2012; 11:841-2; PMID:22336917; http://dx.doi.org/10. 4161/cc.11.5.19461.
23. Vazquez-Martin A, Cufí S, Oliveras-Ferraros C, Menendez JA. Polo-like kinase 1 directs the AMPKmediated activation of myosin regulatory light chain at the cytokinetic cleavage furrow independently of energy balance. Cell Cycle 2012; 11:2422-6; PMID:22672936; http://dx.doi.org/10.4161/cc.20438.
24. Pinter K, Jefferson A, Czibik G, Watkins H, Redwood C. Subunit composition of AMPK trimers present in the cytokinetic apparatus: Implications for drug target identification. Cell Cycle 2012; 11:917-21; PMID:22333580; http://dx.doi.org/10.4161/cc.11.5.19412.
25. Carmena M. A mitosis-specific AMPK trimer? Cell Cycle 2012; 11:1269; PMID:22426423; http://dx.doi.org/10.4161/cc.19902.
26. Banko MR, Allen JJ, Schaffer BE, Wilker EW, Tsou P, White JL, et al. Chemical genetic screen for AMPKα2 substrates uncovers a network of proteins involved in mitosis. Mol Cell 2011; 44:878-92; PMID:22137581; http://dx.doi.org/10.1016/j.molcel.2011.11.005.
27. Robitaille AM, Hall MN. Ramping up mitosis: an AMPKα2-regulated signaling network promotes mitotic progression. Mol Cell 2012; 45:8-9; PMID:22244327; http://dx.doi.org/10.1016/j.molcel.2011.12.018.
28. Wrighton KH. AMPK moonlights in mitosis. Nat Rev Mol Cell Biol 2012; 13:64; PMID:22251904.
29. Thaiparambil JT, Eggers CM, Marcus AI. AMPK regulates mitotic spindle orientation through phosphorylation of myosin regulatory light chain. Mol Cell Biol 2012; 32:3203-17; PMID:22688514; http://dx.doi.org/10.1128/MCB.00418-12.
30. Schmidt T, Wahl P, Wüthrich RP, Vogetseder A, Picard N, Kaissling B, et al. Immunolocalization of phospho-S6 kinases: a new way to detect mitosis in tissue sections and in cell culture. Histochem Cell Biol 2007; 127:123-9; PMID:17136413; http://dx.doi.org/10.1007/s00418-006-0255-5.
31. Egervári G, Márk A, Hajdu M, Barna G, Sápi Z, Krenács T, et al. Mitotic lymphoma cells are characterized by high expression of phosphorylated ribosomal S6 protein. Histochem Cell Biol 2011; 135:409-17; PMID:21424608; http://dx.doi.org/10.1007/s00418-011-0803-5.
32. Rossi R, Pester JM, McDowell M, Soza S, Montecucco A, Lee-Fruman KK. Identification of S6K2 as a centrosome-located kinase. FEBS Lett 2007; 581:4058-64; PMID:17678899; http://dx.doi.org/10.1016/j.febslet.2007.07.047.
33. Gwinn DM, Asara JM, Shaw RJ. Raptor is phosphorylated by cdc2 during mitosis. PLoS One 2010; 5:e9197; PMID:20169205; http://dx.doi.org/10.1371/ journal.pone.0009197.
34. Ramírez-Valle F, Badura ML, Braunstein S, Narasimhan M, Schneider RJ. Mitotic raptor promotes mTORC1 activity, G(2)/M cell cycle progression, and internal ribosome entry site-mediated mRNA translation. Mol Cell Biol 2010; 30:3151-64; PMID:20439490; http://dx.doi.org/10.1128/MCB.00322-09.
35. Vazquez-Martin A, Cufí S, Oliveras-Ferraros C, Menendez JA. Raptor, a positive regulatory subunit of mTOR complex 1, is a novel phosphoprotein of the rDNA transcription machinery in nucleoli and chromosomal nucleolus organizer regions (NORs). Cell Cycle 2011; 10:3140-52; PMID:21900751; http://dx.doi.org/10.4161/cc.10.18.17376.
36. Blagosklonny MV. Aging and immortality: quasiprogrammed senescence and its pharmacologic inhibition. Cell Cycle 2006; 5:2087-102; PMID:17012837; http://dx.doi.org/10.4161/cc.5.18.3288.
37. Blagosklonny MV. An anti-aging drug today: from senescence-promoting genes to anti-aging pill. Drug Discov Today 2007; 12:218-24; PMID:17331886; http://dx.doi.org/10.1016/j.drudis.2007.01.004.
38. Blagosklonny MV. Prevention of cancer by inhibiting aging. Cancer Biol Ther 2008; 7:1520-4; PMID:18769112; http://dx.doi.org/10.4161/cbt.7.10.6663.
39. de Magalhães JP, Faragher RG. Cell divisions and mammalian aging: integrative biology insights from genes that regulate longevity. Bioessays 2008; 30:567-78; PMID:18478536; http://dx.doi.org/10.1002/bies.20760.
40. Blagosklonny MV. Validation of anti-aging drugs by treating age-related diseases. Aging (Albany NY) 2009; 1:281-8; PMID:20157517.
41. Blagosklonny MV. Aging-suppressants: cellular senescence (hyperactivation) and its pharmacologic deceleration. Cell Cycle 2009; 8:1883-7; PMID:19448395; http://dx.doi.org/10.4161/cc.8.12.8815.
42. Blagosklonny MV. TOR-driven aging: speeding car without brakes. Cell Cycle 2009; 8:4055-9; PMID:19923900; http://dx.doi.org/10.4161/cc.8.24.10310.
43. Blagosklonny MV. Rapamycin and quasi-programmed aging: four years later. Cell Cycle 2010; 9:1859-62; PMID:20436272; http://dx.doi.org/10.4161/cc.9.10. 11872.
44. Blagosklonny MV. Molecular damage in cancer: an argument for mTOR-driven aging. Aging (Albany NY) 2011; 3:1130-41; PMID:22246147.
45. Menendez JA, Cufí S, Oliveras-Ferraros C, Vellon L, Joven J, Vazquez-Martin A. Gerosuppressant metformin: less is more. Aging (Albany NY) 2011; 3:348-62; PMID:21483040.
46. Menendez JA, Vellon L, Oliveras-Ferraros C, Cufí S, Vazquez-Martin A. mTOR-regulated senescence and autophagy during reprogramming of somatic cells to pluripotency: a roadmap from energy metabolism to stem cell renewal and aging. Cell Cycle 2011; 10:3658-77; PMID:22052357; http://dx.doi.org/10.4161/ cc.10.21.18128.
47. Blagosklonny MV. Cell cycle arrest is not yet senescence, which is not just cell cycle arrest: terminology for TOR-driven aging. Aging (Albany NY) 2012; 4:159-65; PMID:22394614.